Related Experiment Video
Updated: Dec 17, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Interferon-α2b Treatment for COVID-19.
Qiong Zhou1, Virginia Chen2, Casey P Shannon2
1Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Interferon (IFN)-α2b treatment, with or without arbidol, shortened the duration of detectable SARS-CoV-2 in COVID-19 patients. This antiviral therapy also reduced inflammatory markers like IL-6 and CRP.
Area of Science:
- Virology
- Immunology
- Infectious Diseases
Background:
- The COVID-19 pandemic caused by SARS-CoV-2 lacks approved antiviral treatments.
- Interferon (IFN)-α2b is being explored for its potential therapeutic effects.
Purpose of the Study:
- To investigate the efficacy of nebulized interferon (IFN)-α2b, alone or in combination with arbidol, in hospitalized COVID-19 patients.
- To assess the impact of IFN-α2b on viral shedding and inflammatory markers in SARS-CoV-2 infection.
Main Methods:
- An uncontrolled, exploratory study involving 77 hospitalized adult COVID-19 patients.
- Treatment groups included nebulized IFN-α2b, arbidol, or a combination.
- Monitoring included serial SARS-CoV-2 testing, hematological parameters, cytokine levels, temperature, and oxygen saturation.
Main Results:
- IFN-α2b treatment significantly reduced the duration of detectable SARS-CoV-2 in the upper respiratory tract.
- Combined IFN-α2b and arbidol therapy also shortened viral shedding duration.
- Elevated levels of inflammatory markers, including IL-6 and C-reactive protein (CRP), were reduced in duration.
Conclusions:
- Interferon (IFN)-α2b shows promise as a potential antiviral therapy for COVID-19.
- Further investigation of IFN-α2b is warranted for treating SARS-CoV-2 infections.
More Related Videos
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Immune Response Against Viral Pathogens
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Tonsillitis II: Management
Myocarditis III: Medical Management